Undisclosed Metabolic Program

About Kallyope

Kallyope is a private, clinical-stage biotech translating groundbreaking neuroscience into novel therapeutics for migraine and metabolic diseases. Its lead asset, elismetrep (K-304), is a first-in-class TRPM8 antagonist for migraine entering pivotal studies in 2026, supported by positive Phase 2b data. The company's proprietary Klarity™ platform identifies novel neural circuits, fueling a pipeline that includes a differentiated non-incretin metabolic candidate (K-554) and a discovery partnership with Novo Nordisk. With a seasoned leadership team and backing from top-tier life science investors, Kallyope aims to address large markets with significant unmet need.

About Ochre Bio

Ochre Bio is a private, preclinical-stage biotech pioneering a data-driven approach to liver disease. The company has built a unique 'Human Discovery Platform' combining extensive human liver datasets, AI-driven causal prediction, and validation in sophisticated human ex vivo models like perfused livers. This integrated strategy, coupled with an in-house RNA therapeutic manufacturing capability, aims to rapidly translate novel targets into clinical candidates, as evidenced by a significant partnership with GSK and a pipeline targeting fibrosis and cirrhosis.

Therapeutic Areas

Other Metabolic Disorders Drugs